Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided label excerpt supports the claim that LIPITOR is indicated as an adjunct to diet for individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia when diet/nonpharmacologic measures are inadequate.
Category Scores
Accurate Statements
LIPITOR can be used for therapy to lower lipid levels in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia, as an adjunct to diet.
1 INDICATIONS AND USAGE: “Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.”
Unsupported Statements
Contradictions
Important Omissions
The label language in the excerpt specifies that the diet should be restricted in saturated fat and cholesterol and that nonpharmacologic measures alone have been inadequate; the claim does not mention these qualifiers.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim concerns an indication/usage statement supported by the label; missing qualifiers affect precision of who should receive therapy but are not a direct safety contraindication.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Indication qualifier details from the label excerpt (diet/nonpharmacologic measures inadequacy) are not included in the claim.
Suggested Improvement
Add the label qualifiers that drug therapy is an adjunct to diet when response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.